Sharon Sawchak

1.6k total citations · 3 hit papers
26 papers, 1.1k citations indexed

About

Sharon Sawchak is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Sharon Sawchak has authored 26 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 7 papers in Cardiology and Cardiovascular Medicine and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Sharon Sawchak's work include Cardiac Imaging and Diagnostics (7 papers), Acute Myocardial Infarction Research (5 papers) and Schizophrenia research and treatment (5 papers). Sharon Sawchak is often cited by papers focused on Cardiac Imaging and Diagnostics (7 papers), Acute Myocardial Infarction Research (5 papers) and Schizophrenia research and treatment (5 papers). Sharon Sawchak collaborates with scholars based in United States, United Kingdom and Estonia. Sharon Sawchak's co-authors include Stephen K. Brannan, Andrew Miller, Alan Breier, Ann M. Saunders, Marina Zvartau‐Hind, Michael C. Irizarry, Steven M. Paul, Jeffrey A. Lieberman, Michael Gold and Gary E. Landreth and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Sharon Sawchak

25 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia

2021 216 citations Stephen K. Brannan, Sharon Sawchak et al. New England Journal of Medicine profile →
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial

2023 104 citations Inder Kaul, Sharon Sawchak et al. The Lancet profile →
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia

2024 71 citations Inder Kaul, Sharon Sawchak et al. profile →

Peers

Countries citing papers authored by Sharon Sawchak

Since Specialization

Citations

This map shows the geographic impact of Sharon Sawchak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon Sawchak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon Sawchak more than expected).

Fields of papers citing papers by Sharon Sawchak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon Sawchak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon Sawchak. The network helps show where Sharon Sawchak may publish in the future.

Co-authorship network of co-authors of Sharon Sawchak

This figure shows the co-authorship network connecting the top 25 collaborators of Sharon Sawchak. A scholar is included among the top collaborators of Sharon Sawchak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharon Sawchak. Sharon Sawchak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial 2026 ·American Journal of Psychiatry ·Inder Kaul, Amy Claxton, Colin Sauder, (unknown), (unknown), (unknown), (unknown), (unknown), Sharon Sawchak, Stephen K. Brannan	1
2	Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia 2025 ·The Journal of Clinical Psychiatry ·Inder Kaul, Amy Claxton, Sharon Sawchak, Colin Sauder, Stephen K. Brannan, (unknown), (unknown), (unknown), David T. Brown, Andrew J. Cutler, Ronald N. Marcus	4
3	EFFICACY OF KARXT ON NEGATIVE SYMPTOMS IN ACUTE SCHIZOPHRENIA: AN ANALYSIS OF POOLED DATA FROM 3 TRIALS 2025 ·The International Journal of Neuropsychopharmacology ·Scott Vuocolo, William P. Horan, Amy Claxton, Steven D. Targum, Inder Kaul, Sharon Sawchak, Andrew C. Miller, Steven M. Paul, Stephen K. Brannan	0
4	Safety and Tolerability of KarXT (Xanomeline Trospium): Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials 2024 ·CNS Spectrums ·Stephen K. Brannan, Andrew J. Cutler, Sharon Sawchak, Judith C. Kando, Andrew Miller, Amy Claxton, Steven M. Paul, Inder Kaul	1
5	Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials 2024 ·SHILAP Revista de lepidopterología ·Inder Kaul, Sharon Sawchak, Amy Claxton, Colin Sauder, (unknown), Rishi Kakar, David P. Walling, Leslie Citrome, Haiyuan Zhu, Andrew Miller, Stephen K. Brannan	13
6	Efficacy of KarXT (Xanomeline Trospium) in Schizophrenia: Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials 2024 ·CNS Spectrums ·Inder Kaul, Leslie Citrome, Sharon Sawchak, Judith C. Kando, Andrew Miller, Steven M. Paul, Stephen K. Brannan	1
7	Safety and efficacy of KarXT (Xanomeline Trospium) in Schizophrenia in the Phase 3, Randomized, Double-Blind, Placebo-Controlled EMERGENT-2 Trial 2023 ·CNS Spectrums ·Christoph U. Correll, Andrew C. Miller, Sharon Sawchak, Inder Kaul, Steven M. Paul, Stephen K. Brannan	8
8	Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial breakdown → 2023 ·The Lancet ·Inder Kaul, Sharon Sawchak, Christoph U. Correll, Rishi Kakar, Alan Breier, Haiyuan Zhu, Andrew Miller, Steven M. Paul, Stephen K. Brannan	104
9	Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia breakdown → 2021 ·New England Journal of Medicine ·Stephen K. Brannan, Sharon Sawchak, Andrew Miller, Jeffrey A. Lieberman, Steven M. Paul, Alan Breier	216
10	Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies 2011 ·Current Alzheimer Research ·Conn Harrington, Sharon Sawchak, Carl Chiang, J. Davies, (unknown), Ann M. Saunders, Michael C. Irizarry, (unknown), Marina Zvartau‐Hind, C H van Dyck, Maike Gold	157
11	Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study 2010 ·Dementia and Geriatric Cognitive Disorders ·Michael Gold, Claire Alderton, Marina Zvartau‐Hind, (unknown), Ann M. Saunders, Michael C. Irizarry, Suzanne Craft, Gary E. Landreth, Ülla Linnamägi, Sharon Sawchak	287
12	P4‐299: Effects Of Rosiglitazone‐extended Release As Adjunctive Therapy To Acetylcholinesterase Inhibitors Over 48 Weeks On Cognition In Apoe4‐stratified Subjects With Mild‐to‐moderate Alzheimer's Disease 2009 ·Alzheimer s & Dementia ·Conn Harrington, Sharon Sawchak, Carl Chiang, John T. Davies, Ann M. Saunders, Michael C. Irizarry, Marina Zvartau‐Hind, Christopher van Dyck, Michael Gold	7
13	P1‐245: Safety and tolerability of rosiglitazone XR in a randomised, placebo‐controlled study in APOE4‐stratified subjects with mild‐to‐moderate Alzheimer's disease 2009 ·Alzheimer s & Dementia ·Marina Zvartau‐Hind, Claire Alderton, (unknown), Ann M. Saunders, Michael C. Irizarry, Suzanne Craft, Gary E. Landreth, Ülla Linnamägi, Sharon Sawchak, Michael Gold	1
14	Electrocardiographic Differentiation of the ST-Segment Depression of Acute Myocardial Injury Due to the Left Circumflex Artery Occlusion from that of Myocardial Ischemia of Nonocclusive Etiologies 1997 ·The American Journal of Cardiology ·Akbar Shah, Galen S. Wagner, Cynthia L. Green, Suzanne W. Crater, Sharon Sawchak, Nancy M. Wildermann, Daniel B. Mark, Robert Waugh, Mitchell W. Krucoff	42
15	Performance of an automated real-time ST-segment analysis program to detect coronary occlusion and reperfusion 1996 ·Journal of Electrocardiology ·Rolf F. Veldkamp, Sharon Sawchak, James E. Pope, Robert M. Califf, Mitchell W. Krucoff	8
16	Simultaneous ST-segment measurements using standard and monitoring-compatible torso limb lead placements at rest and during coronary occlusion 1994 ·The American Journal of Cardiology ·Mitchell W. Krucoff, (unknown), Wesley K. Haisty, James E. Pope, Sharon Sawchak, G. Wagner, Olle Pahlm	24
17	From signal/noise to information content/noise 1994 ·Journal of Electrocardiology ·Mitchell W. Krucoff, (unknown), Frank E. Harrell, (unknown), (unknown), (unknown), Sharon Sawchak, James E. Pope, Akbar Shah, C. B. Granger, Robert M. Califf, (unknown)	3
18	Comparison of continuous ST-segment recovery analysis with methods using static electrocardiograms for noninvasive patency assessment during acute myocardial infarction 1994 ·The American Journal of Cardiology ·Rolf F. Veldkamp, (unknown), (unknown), James E. Pope, Sharon Sawchak, (unknown), Robert M. Califf, Galen S. Wagner, (unknown)	33
19	Continuously updated 12-lead ST-segment recovery analysis for myocardial infarct artery patency assessment and its correlation with multiple simultaneous early angiographic observations 1993 ·The American Journal of Cardiology ·Mitchell W. Krucoff, (unknown), James E. Pope, Karen S. Pieper, Prapti Kanani, Christopher B. Granger, Rolf F. Veldkamp, B L Wagner, Sharon Sawchak, Robert M. Califf	126
20	Evolution of an automated ST-segment analysis program for dynamic real-time, noninvasive detection of coronary occlusion and reperfusion 1992 ·Journal of Electrocardiology ·Rolf F. Veldkamp, James R. Bengtson, Sharon Sawchak, James E. Pope, (unknown), David Mortara, Robert M. Califf, Mitchell W. Krucoff	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact